Ultragenyx Pharmaceutical RARE
$16.48 −$0.74 (-4.30%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $16.50 +0.12%
Open$16.94
Prev close$17.22
Day range$16.43 – $17.35
Volume3.01M
Market cap$1.68B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$173.00M+8.1% YoY
Operating profit-$110.00M+35.7% YoY
Net profit-$118.00M+34.4% YoY
Diluted EPS-$1.16+35.9% YoY
Free cash flow-$45.00M+51.1% YoY
Operating cash flow-$43.00M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin82.9%
Operating margin-64.0%
Net margin-71.8%
Return on assets-44.1%
Current ratio1.40
Liabilities / assets131.1%
Cash & investments$266.00M
Net cash (debt)$266.00M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $173.00M | $214.00M | $136.00M | $673.00M | $207.00M |
| Total Operating Revenue | $173.00M | $214.00M | $136.00M | $673.00M | $207.00M |
| Cost of Revenue | $32.00M | $34.00M | $30.00M | $109.00M | $29.00M |
| Gross Profit | $141.00M | $180.00M | $106.00M | $564.00M | $178.00M |
| Operating Expense | $251.00M | $255.00M | $275.00M | $1.10B | $291.00M |
| Selling and Admin Expenses | $97.00M | $88.00M | $88.00M | $349.00M | $88.00M |
| Research & Development | $154.00M | $167.00M | $187.00M | $750.00M | $203.00M |
| Operating Profit | -$110.00M | -$75.00M | -$169.00M | -$535.00M | -$113.00M |
| Net Non-Operating Interest Income (Expense) | -$17.00M | -$17.00M | -$15.00M | -$37.00M | -$14.00M |
| Non-Operating Interest Income | $3.00M | $5.00M | $6.00M | $25.00M | $6.00M |
| Non-Operating Interest Expense | $20.00M | $22.00M | $21.00M | $62.00M | $20.00M |
| Pretax Profit | -$127.00M | -$91.00M | -$184.00M | -$571.00M | -$128.00M |
| Tax | -$9.00M | $1.00M | $1.00M | $4.00M | $1.00M |
| Net Profit | -$118.00M | -$92.00M | -$185.00M | -$575.00M | -$129.00M |
| Profit from Continuing Operations | -$118.00M | -$92.00M | -$185.00M | -$575.00M | -$129.00M |
| Net Income to Parent Company | -$118.00M | -$92.00M | -$185.00M | -$575.00M | -$129.00M |
| Net Income to Common Stockholders | -$118.00M | -$92.00M | -$185.00M | -$575.00M | -$129.00M |
| Basic EPS | -$1.16 | -$0.90 | -$1.84 | -$5.83 | -$1.29 |
| Diluted EPS | -$1.16 | -$0.90 | -$1.84 | -$5.83 | -$1.29 |
| Other Income (Expense) | – | $1.00M | – | $1.00M | -$1.00M |
| Other Non-Operating Income (Expenses) | – | $1.00M | – | $1.00M | -$1.00M |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.19B | $1.26B | $1.30B | $1.53B | $1.53B |
| Total Current Assets | $544.00M | $606.00M | $657.00M | $951.00M | $951.00M |
| Cash and Cash Equivalents & Short-Term Investments | $266.00M | $292.00M | $413.00M | $680.00M | $680.00M |
| -Cash and Cash Equivalents | $150.00M | $125.00M | $175.00M | $421.00M | $421.00M |
| -Short Term Investments | $116.00M | $167.00M | $238.00M | $259.00M | $259.00M |
| Receivables | $166.00M | $200.00M | $121.00M | $158.00M | $158.00M |
| -Accounts Receivable | $166.00M | $200.00M | $121.00M | $158.00M | $158.00M |
| Inventory | $59.00M | $59.00M | $55.00M | $52.00M | $52.00M |
| Other Current Assets | $53.00M | $55.00M | $68.00M | $61.00M | $61.00M |
| Total Non-Current Assets | $643.00M | $658.00M | $639.00M | $581.00M | $581.00M |
| Net PPE | $231.00M | $235.00M | $239.00M | $244.00M | $244.00M |
| Investments and Advances | $135.00M | $144.00M | $121.00M | $57.00M | $57.00M |
| -Available for Sale Securities | $135.00M | $144.00M | $121.00M | $57.00M | $57.00M |
| Goodwill and Other Intangible Assets | $214.00M | $216.00M | $218.00M | $220.00M | $220.00M |
| -Goodwill | $44.00M | $44.00M | $44.00M | $44.00M | $44.00M |
| -Other Intangible Assets | $170.00M | $172.00M | $174.00M | $176.00M | $176.00M |
| Other Non-Current Assets | $63.00M | $63.00M | $61.00M | $60.00M | $60.00M |
| Total Liabilities | $1.56B | $1.55B | $1.53B | $1.61B | $1.61B |
| Total Current Liabilities | $389.00M | $351.00M | $325.00M | $384.00M | $384.00M |
| Payables | $45.00M | $39.00M | $42.00M | $31.00M | $31.00M |
| -Accounts Payable | $45.00M | $39.00M | $42.00M | $31.00M | $31.00M |
| Current Accrued Expenses | $162.00M | $149.00M | $133.00M | $208.00M | $208.00M |
| Current Provisions | $80.00M | $72.00M | $61.00M | $57.00M | $57.00M |
| Other Current Liabilities | $102.00M | $91.00M | $89.00M | $76.00M | $76.00M |
| Total Non-Current Liabilities | $1.17B | $1.20B | $1.20B | $1.22B | $1.22B |
| Non-Current Deferred Liabilities | $21.00M | $30.00M | $30.00M | $30.00M | $30.00M |
| Other Non-Current Liabilities | $40.00M | $41.00M | $42.00M | $20.00M | $20.00M |
| Total Equity | -$369.00M | -$284.00M | -$229.00M | -$73.00M | -$73.00M |
| Stockholders' Equity | -$376.00M | -$291.00M | -$236.00M | -$80.00M | -$80.00M |
| Capital Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| -Common Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $4.55B | $4.52B | $4.48B | $4.45B | $4.45B |
| Retained Earnings | -$4.93B | -$4.81B | -$4.72B | -$4.53B | -$4.53B |
| Less: Treasury Stock | -$10.00M | -$10.00M | -$10.00M | -$8.00M | -$8.00M |
| Gains/Losses Not Affecting Retained Earnings | -$1.00M | $0.00 | $0.00 | $1.00M | $1.00M |
| Other Equity Interests | $10.00M | $10.00M | $10.00M | $8.00M | $8.00M |
| Minority Interests | $7.00M | $7.00M | $7.00M | $7.00M | $7.00M |
| -Gross PPE | – | – | – | $380.00M | $380.00M |
| -Accumulated Depreciation | – | – | – | -$136.00M | -$136.00M |
| Short-Term Debt and Capital Lease Obligation | – | – | – | $12.00M | $12.00M |
| -Current Capital Lease Obligation | – | – | – | $12.00M | $12.00M |
| Long Term Debt and Capital Lease Obligation | – | – | – | $24.00M | $24.00M |
| -Long Term Capital Lease Obligation | – | – | – | $24.00M | $24.00M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$43.00M | -$97.00M | -$197.00M | -$466.00M | -$100.00M |
| Net cash flow from continuing operations | -$43.00M | -$97.00M | -$197.00M | -$466.00M | -$100.00M |
| Net Income from Continuing Operations | -$118.00M | -$92.00M | -$185.00M | -$575.00M | -$129.00M |
| Depreciation & Depletion & Amortization | $9.00M | $8.00M | $8.00M | $35.00M | $9.00M |
| Other Non-Cash Items | -$4.00M | -$18.00M | $2.00M | -$52.00M | -$17.00M |
| Change in Working Capital | $46.00M | -$29.00M | -$51.00M | -$23.00M | $0.00 |
| -Change in Receivables | $23.00M | -$62.00M | $19.00M | -$31.00M | -$34.00M |
| -Change in Inventory | -$1.00M | -$3.00M | -$4.00M | -$6.00M | $0.00 |
| -Change in Prepaid Assets | -$1.00M | $12.00M | -$9.00M | -$10.00M | -$3.00M |
| -Change in Payables and Accrued Expense | $25.00M | $24.00M | -$57.00M | $24.00M | $37.00M |
| Net cash flow from investing | $58.00M | $44.00M | -$49.00M | $236.00M | -$72.00M |
| Net Cash Flow from Continuing Investing Activities | $58.00M | $44.00M | -$49.00M | $236.00M | -$72.00M |
| Net PPE Purchase and Sale | -$2.00M | -$1.00M | -$1.00M | -$6.00M | -$1.00M |
| Net Intangibles Purchase and Sale | $0.00 | $0.00 | -$5.00M | -$15.00M | $0.00 |
| Net Investment Purchase and Sale | $59.00M | $48.00M | -$43.00M | $258.00M | -$72.00M |
| Net Other Investing Changes | $1.00M | – | – | -$1.00M | $1.00M |
| Financing Cash Flow | $10.00M | – | – | $478.00M | $394.00M |
| Net Cash Flow from Continuing Financing Activities | $10.00M | – | – | $478.00M | $394.00M |
| Net Common Stock Issuance | $10.00M | – | – | $86.00M | $2.00M |
| Ending Cash Balance | $164.00M | $140.00M | $189.00M | $436.00M | $436.00M |
| Net Change in Cash | $25.00M | -$50.00M | -$246.00M | $248.00M | $222.00M |
| Beginning Cash Balance | $140.00M | $189.00M | $436.00M | $184.00M | $215.00M |
| Effect of Exchange Rate Changes | -$1.00M | $1.00M | -$1.00M | $4.00M | -$1.00M |
| Free Cash Flow | -$45.00M | -$98.00M | -$203.00M | -$487.00M | -$101.00M |
| Net Other Financing Charges | – | – | – | $392.00M | – |
No comments yet — be the first to weigh in on RARE.
Sign in to join the discussion.